The microbiome is increasingly becoming the newest frontier in life sciences with scientists mining for potential discoveries. Microbiome therapy includes probiotics, Fecal Microbiota Transplant (FMT), prebiotics, or engineered microbes to cure diseases, such as C. difficile infection, inflammatory bowel disease and metabolic disorders. The increase in research initiatives and rising number of gut infections along with enhanced microbiome sequencing capabilities is resulting in the positive growth of the microbiome therapeutics industry. The main aim of microbiome therapeutic products is to restore and maintain the normal balance and healthy function of organisms or microbiota in the gut. Researchers, investors and business owners are closely observing the development of microbiome therapeutics.
Fueled by these factors, Fortune Business Insights states that the market for microbiome therapeutics reached USD 288.8 million in 2025. It is anticipated to hit USD 4,023.1 million in 2034, with a CAGR of 34.90% during the forecast period.